vs
Rithm Capital Corp.（RITM）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Rithm Capital Corp.的季度营收约是Revvity的1.1倍（$828.2M vs $772.1M），Rithm Capital Corp.净利率更高（13.2% vs 12.7%，领先0.5%），Rithm Capital Corp.同比增速更快（508.5% vs 5.9%），过去两年Revvity的营收复合增速更高（9.0% vs -17.9%）
Rithm Capital Corp.是总部位于美国纽约的投资管理机构，核心业务聚焦房地产投资与另类资产投资，依托专业的投研团队和成熟的市场运营经验，为合作伙伴及投资者提供优质的资产配置解决方案与长期收益回报。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
RITM vs RVTY — 直观对比
营收规模更大
RITM
是对方的1.1倍
$772.1M
营收增速更快
RITM
高出502.6%
5.9%
净利率更高
RITM
高出0.5%
12.7%
两年增速更快
RVTY
近两年复合增速
-17.9%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $828.2M | $772.1M |
| 净利润 | $109.5M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 29.9% | 14.5% |
| 净利率 | 13.2% | 12.7% |
| 营收同比 | 508.5% | 5.9% |
| 净利润同比 | 27.7% | 3.9% |
| 每股收益（稀释后） | $0.12 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RITMRVTY
| Q1 26 | $828.2M | — | ||
| Q4 25 | $1.5B | $772.1M | ||
| Q3 25 | $1.1B | $698.9M | ||
| Q2 25 | $1.2B | $720.3M | ||
| Q1 25 | $768.4M | $664.8M | ||
| Q4 24 | $2.1B | $729.4M | ||
| Q3 24 | $619.5M | $684.0M | ||
| Q2 24 | $1.2B | $691.7M |
净利润RITMRVTY
| Q1 26 | $109.5M | — | ||
| Q4 25 | $85.0M | $98.4M | ||
| Q3 25 | $221.5M | $46.7M | ||
| Q2 25 | $311.7M | $53.9M | ||
| Q1 25 | $78.8M | $42.2M | ||
| Q4 24 | $290.2M | $94.6M | ||
| Q3 24 | $121.7M | $94.4M | ||
| Q2 24 | $235.6M | $55.4M |
毛利率RITMRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% |
营业利润率RITMRVTY
| Q1 26 | 29.9% | — | ||
| Q4 25 | 13.8% | 14.5% | ||
| Q3 25 | 21.4% | 11.7% | ||
| Q2 25 | 25.2% | 12.6% | ||
| Q1 25 | 7.4% | 10.9% | ||
| Q4 24 | 23.8% | 16.3% | ||
| Q3 24 | 7.3% | 14.3% | ||
| Q2 24 | 23.6% | 12.4% |
净利率RITMRVTY
| Q1 26 | 13.2% | — | ||
| Q4 25 | 5.7% | 12.7% | ||
| Q3 25 | 20.0% | 6.7% | ||
| Q2 25 | 25.6% | 7.5% | ||
| Q1 25 | 10.3% | 6.4% | ||
| Q4 24 | 14.0% | 13.0% | ||
| Q3 24 | 19.7% | 13.8% | ||
| Q2 24 | 19.2% | 8.0% |
每股收益（稀释后）RITMRVTY
| Q1 26 | $0.12 | — | ||
| Q4 25 | $0.09 | $0.86 | ||
| Q3 25 | $0.35 | $0.40 | ||
| Q2 25 | $0.53 | $0.46 | ||
| Q1 25 | $0.07 | $0.35 | ||
| Q4 24 | $0.50 | $0.77 | ||
| Q3 24 | $0.20 | $0.77 | ||
| Q2 24 | $0.43 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $9.1B | $7.3B |
| 总资产 | $53.4B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RITMRVTY
| Q1 26 | — | — | ||
| Q4 25 | $1.8B | $919.9M | ||
| Q3 25 | $1.6B | $931.4M | ||
| Q2 25 | $1.6B | $991.8M | ||
| Q1 25 | $1.5B | $1.1B | ||
| Q4 24 | $1.5B | $1.2B | ||
| Q3 24 | $1.6B | $1.2B | ||
| Q2 24 | $1.2B | $2.0B |
总债务RITMRVTY
| Q1 26 | — | — | ||
| Q4 25 | $35.4B | — | ||
| Q3 25 | $32.2B | — | ||
| Q2 25 | $31.2B | — | ||
| Q1 25 | $32.2B | — | ||
| Q4 24 | $32.6B | — | ||
| Q3 24 | $29.6B | — | ||
| Q2 24 | $30.1B | — |
股东权益RITMRVTY
| Q1 26 | $9.1B | — | ||
| Q4 25 | $8.4B | $7.3B | ||
| Q3 25 | $8.5B | $7.4B | ||
| Q2 25 | $7.9B | $7.6B | ||
| Q1 25 | $7.8B | $7.6B | ||
| Q4 24 | $7.8B | $7.7B | ||
| Q3 24 | $7.7B | $7.9B | ||
| Q2 24 | $7.3B | $7.9B |
总资产RITMRVTY
| Q1 26 | $53.4B | — | ||
| Q4 25 | $53.1B | $12.2B | ||
| Q3 25 | $47.2B | $12.1B | ||
| Q2 25 | $44.3B | $12.4B | ||
| Q1 25 | $45.3B | $12.4B | ||
| Q4 24 | $46.0B | $12.4B | ||
| Q3 24 | $42.3B | $12.8B | ||
| Q2 24 | $42.0B | $13.4B |
负债/权益比RITMRVTY
| Q1 26 | — | — | ||
| Q4 25 | 4.20× | — | ||
| Q3 25 | 3.79× | — | ||
| Q2 25 | 3.92× | — | ||
| Q1 25 | 4.14× | — | ||
| Q4 24 | 4.18× | — | ||
| Q3 24 | 3.87× | — | ||
| Q2 24 | 4.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流RITMRVTY
| Q1 26 | — | — | ||
| Q4 25 | $-114.6M | $182.0M | ||
| Q3 25 | $-2.0B | $138.5M | ||
| Q2 25 | $-557.1M | $134.3M | ||
| Q1 25 | $1.4B | $128.2M | ||
| Q4 24 | $-1.8B | $174.2M | ||
| Q3 24 | $768.1M | $147.9M | ||
| Q2 24 | $-55.7M | $158.6M |
自由现金流RITMRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M |
自由现金流率RITMRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% |
资本支出强度RITMRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% |
现金转化率RITMRVTY
| Q1 26 | — | — | ||
| Q4 25 | -1.35× | 1.85× | ||
| Q3 25 | -9.22× | 2.97× | ||
| Q2 25 | -1.79× | 2.49× | ||
| Q1 25 | 18.03× | 3.03× | ||
| Q4 24 | -6.04× | 1.84× | ||
| Q3 24 | 6.31× | 1.57× | ||
| Q2 24 | -0.24× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RITM
| Servicing revenue, net | $375.1M | 45% |
| Other | $234.9M | 28% |
| Gain on originated residential mortgage loans, held-for-sale, net | $195.0M | 24% |
| Other revenue | $23.3M | 3% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
